Akiram Therapeutics

Executive Summary

Akiram Therapeutics, a Stockholm-based private company founded in 2022, is pioneering targeted radioimmunotherapy for solid cancers. The company combines antibodies with radioactive isotopes to deliver precise radiation to tumor cells, aiming to achieve both diagnostic imaging and therapeutic effect (theranostics). Preclinical studies have demonstrated promising tumor targeting and efficacy, positioning the company to enter clinical development. Akiram's approach could address significant unmet needs in difficult-to-treat cancers, offering a differentiated modality with potential for improved specificity and reduced off-target toxicity compared to conventional radiotherapy or antibody-drug conjugates. As a pre-clinical-stage company, Akiram faces typical early-stage risks including funding requirements, regulatory hurdles, and the inherent uncertainty of translating preclinical results to humans. The company has not disclosed total funding or valuation, and no pipeline candidates have been publicly named. However, the growing interest in radiopharmaceuticals and promising preclinical data suggest potential for advancement. Success will depend on securing financing, achieving IND filing, and demonstrating safety and efficacy in first-in-human trials. Akiram's Swedish base provides access to European research networks and potential non-dilutive funding sources.

Upcoming Catalysts (preview)

• Q4 2026IND filing for lead candidate30% success
• Q2 2026Presentation of preclinical data at major oncology conference80% success
• Q3 2026Series A funding round or partnership announcement50% success